JANUX THERAPEUTICS INC (JANX) — insider trading
Health Care · NASDAQ
JANUX THERAPEUTICS INC (JANX) has 20 reported SEC Form 4 insider transactions in our data, including 2 open-market sales among the most recent 20 (latest 2026-07-08).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-08 | Campbell David Alan | Director, Officer (President and CEO) | Option exercise / conversion (derivative) | 7,000 | $0.00 | $0 | Form 4 |
| 2026-07-08 | Campbell David Alan | Director, Officer (President and CEO) | Option exercise / conversion | 7,000 | $4.21 | $29.5K | Form 4 |
| 2026-06-11 | Barrett Ronald W | Director | Grant / award / vesting (derivative) | 15,500 | $0.00 | $0 | Form 4 |
| 2026-06-11 | Barrett Ronald W | Director | Grant / award / vesting | 5,500 | $0.00 | $0 | Form 4 |
| 2026-06-11 | CAPPS VICKIE L | Director | Grant / award / vesting (derivative) | 15,500 | $0.00 | $0 | Form 4 |
| 2026-06-11 | CAPPS VICKIE L | Director | Grant / award / vesting | 5,500 | $0.00 | $0 | Form 4 |
| 2026-06-11 | DOBMEIER ERIC | Director | Grant / award / vesting (derivative) | 15,500 | $0.00 | $0 | Form 4 |
| 2026-06-11 | DOBMEIER ERIC | Director | Grant / award / vesting | 5,500 | $0.00 | $0 | Form 4 |
| 2026-06-11 | Hernday Natasha | Director | Grant / award / vesting (derivative) | 15,500 | $0.00 | $0 | Form 4 |
| 2026-06-11 | Hernday Natasha | Director | Grant / award / vesting | 5,500 | $0.00 | $0 | Form 4 |
| 2026-06-11 | Kung Winston | Director | Grant / award / vesting (derivative) | 15,500 | $0.00 | $0 | Form 4 |
| 2026-06-11 | Kung Winston | Director | Grant / award / vesting | 5,500 | $0.00 | $0 | Form 4 |
| 2026-06-11 | Simson Jake | Director | Grant / award / vesting (derivative) | 15,500 | $0.00 | $0 | Form 4 |
| 2026-06-11 | Simson Jake | Director | Grant / award / vesting | 5,500 | $0.00 | $0 | Form 4 |
| 2026-06-11 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Grant / award / vesting (derivative) | 15,500 | $0.00 | $0 | Form 4 |
| 2026-06-11 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Grant / award / vesting | 5,500 | $0.00 | $0 | Form 4 |
| 2026-06-02 | Doyle Janeen Noel | Officer (Chief Corp. & Bus. Dev. Ofcr) | Open-market sale | 4,059 | $14.03 | $56.9K | Form 4 |
| 2026-05-11 | Dobek Maria | Officer (Vice President, Accounting) | Open-market sale | 2,038 | $14.17 | $28.9K | Form 4 |
| 2026-02-02 | Go William | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 154,000 | $0.00 | $0 | Form 4 |
| 2026-02-02 | Go William | Officer (Chief Medical Officer) | Grant / award / vesting | 44,000 | $0.00 | $0 | Form 4 |
Ask the chat about JANX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: JANUX THERAPEUTICS INC (JANX).
Last updated 2026-07-08 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.